Edition:
United States

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.70USD
15 Dec 2017
Change (% chg)

$0.01 (+0.59%)
Prev Close
$1.69
Open
$1.70
Day's High
$1.72
Day's Low
$1.67
Volume
32,768
Avg. Vol
86,126
52-wk High
$3.74
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

Moleculin's WP1066 Drug Gets FDA Brain Tumor IND Clearance
Tuesday, 5 Dec 2017 07:00am EST 

Dec 5 (Reuters) - Moleculin Biotech Inc ::MOLECULIN'S WP1066 DRUG GETS FDA BRAIN TUMOR IND CLEARANCE.MOLECULIN BIOTECH-IND APPLICATION FOR PHASE I TRIAL OF WP1066 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA, BRAIN METASTASIS FROM MELANOMA, ALLOWED BY FDA.  Full Article

Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA
Monday, 4 Dec 2017 07:40am EST 

Dec 4 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING.  Full Article

Moleculin Biotech Q3 loss per share $0.14‍​
Tuesday, 14 Nov 2017 07:00am EST 

Nov 14 (Reuters) - Moleculin Biotech Inc : :Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017.Moleculin Biotech Inc - qtrly loss per share $0.14‍​.  Full Article

Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors
Wednesday, 1 Nov 2017 07:30am EDT 

Nov 1 (Reuters) - Moleculin Biotech Inc :Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors.Moleculin-Responses to FDA requests for more information regarding physician-sponsored ind for WP1066 as potential treatment for brain tumors submitted​.  Full Article

Moleculin requests for clinical trial authorization to study annamycin
Tuesday, 24 Oct 2017 07:30am EDT 

Oct 24 (Reuters) - Moleculin Biotech Inc ::Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland.  Full Article

Moleculin announces strategic collaboration to develop immune stimulation drug
Wednesday, 11 Oct 2017 07:30am EDT 

Oct 11 (Reuters) - Moleculin Biotech Inc ::Moleculin announces strategic collaboration to develop immune stimulation drug.Moleculin Biotech - ‍entered into an agreement to collaborate with University of Bergen to expand research on inhibition of brain metastasis by moleculin's pre-clinical drug WP1066​.Moleculin biotech - ‍Moleculin anticipates clinical trial for drug to be ready to begin by end of this year​.Moleculin Biotech - investigational new drug ‍application to study WP1066 ‍in patients with glioblastoma and melanoma has been on hold pending responses to requests from FDA​.Moleculin Biotech - ‍anticipates clinical trial on WP1066 to begin by end of the year. If FDA allows the IND application to proceed based on responses provided​.  Full Article

Moleculin announces FDA approval of Annamycin IND
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Moleculin Biotech Inc :Moleculin announces FDA approval of Annamycin IND.Moleculin Biotech - ‍U.S. IND allows Moleculin to make submission to Polish authorities for planned Annamycin clinical trial to be conducted in Poland​.  Full Article

Moleculin Biotech says ‍entered into an at market issuance sales agreement with Roth Capital Partners LLC and National Securities Corp
Friday, 15 Sep 2017 05:27pm EDT 

Sept 15 (Reuters) - Moleculin Biotech Inc :Moleculin Biotech says ‍entered into an at market issuance sales agreement with Roth Capital Partners, LLC and National Securities Corp.Moleculin Biotech says pursuant to terms of agreement, co may sell through agents shares of co's common stock of up to $13 million​.  Full Article

Moleculin engages CRO to begin clinical trials of WP1220 for the treatment of cutaneous T-Cell lymphoma
Wednesday, 13 Sep 2017 07:30am EDT 

Sept 13 (Reuters) - Moleculin Biotech Inc :Moleculin engages CRO to begin clinical trials of WP1220 for the treatment of cutaneous T-Cell lymphoma.Moleculin Biotech - ‍engaged contract research organization Bioscience to prepare for proof-of-concept clinical trial in Poland.  Full Article

Moleculin to combine brain cancer drug candidate with Roche's Avastin
Wednesday, 6 Sep 2017 07:30am EDT 

Sept 6 (Reuters) - Moleculin Biotech Inc :Moleculin to collaborate on combining its WP1122 brain cancer drug candidate with Roche's drug Avastin.Moleculin Biotech - ‍entered collaborative agreement with University Of Bergen to test WP1122 in combination with drug Avastin made by Roche Pharma​.Moleculin Biotech Inc - Roche Pharma is not a party to collaborative agreement with University Of Bergen​.  Full Article

BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA

* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [http://bit.ly/2jcVpeo] Further company coverage: